A carregar...
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report
RATIONALE: Follicular non-Hodgkin lymphoma (fNHL) is a neoplasm characterized by an indolent course and chemosensitivity, but also by disease recurrence. Bendamustine is often used as frontline treatment or second line. HEADING DIAGNOSIS: fNHL. PATIENT CONCERNS: A 63-year-old Caucasian male with dia...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7437798/ https://ncbi.nlm.nih.gov/pubmed/32871991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021440 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|